What's Happening?
Eli Lilly and Company has announced a significant acquisition of Kelonia Therapeutics, a gene delivery biotech, for up to $7 billion. This move marks Lilly's second major investment in the CAR T space,
following its $2.4 billion acquisition of Orna Therapeutics earlier this year. The acquisition includes Kelonia's Phase 1 lentiviral in vivo CAR-T therapy, KLN-1010, and its innovative gene delivery and integration technology, iGPS. This platform utilizes lentiviral-based particles to deliver T-cells, allowing the patient's body to generate its own CAR T therapies, potentially eliminating complex manufacturing processes and pre-treatment chemotherapy. The deal is expected to close in the second half of 2026, with Lilly paying $3.25 billion upfront and additional payments contingent on milestone achievements.
Why It's Important?
The acquisition of Kelonia Therapeutics by Eli Lilly is a strategic move to expand its presence in genetic medicines, particularly in the oncology and immunology sectors. The integration of Kelonia's iGPS technology could significantly enhance Lilly's capabilities in developing in vivo CAR T therapies, which are considered a promising but unproven area in cancer treatment. This acquisition positions Lilly to compete with major players like Gilead Sciences, AbbVie, and Bristol Myers Squibb in the CAR T space. The deal reflects Lilly's commitment to diversifying its oncology portfolio beyond small molecules and antibodies, aiming for durable growth in the sector. The financial strength of Lilly supports this high-risk investment, potentially leading to breakthroughs in treating conditions like multiple myeloma.
What's Next?
Following the acquisition, Eli Lilly is expected to integrate Kelonia's gene delivery technology into its existing oncology and immunology franchises. The company will likely focus on advancing the development of KLN-1010 and exploring applications of the iGPS technology for other conditions. As the deal progresses, Lilly will face competition from established companies in the CAR T field, necessitating strategic collaborations and continued investment in research and development. The success of this acquisition could pave the way for further expansion in genetic medicines, potentially influencing future mergers and acquisitions in the biotech industry.
